3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
314
Carcinoma, Non-Small-Cell Lung
162
Breast Neoplasms
125
Neoplasm Metastasis
106
Melanoma
95
Leukemia, Myeloid, Acute
80
Lymphoma
79
Multiple Myeloma
74
Colorectal Neoplasms
73
Ovarian Neoplasms
70
Lymphoma, Non-Hodgkin
63
Recurrence
58
Prostatic Neoplasms
56
Pancreatic Neoplasms
51
Lung Neoplasms
50
Carcinoma, Renal Cell
40
Glioblastoma
39
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Lymphoma, Large B-Cell, Diffuse
37
Leukemia, Lymphocytic, Chronic, B-Cell
37
Advanced Solid Tumors
37
Leukemia
36
Myelodysplastic Syndromes
35
Triple Negative Breast Neoplasms
34
Head and Neck Neoplasms
33
Sarcoma
31
Brain Neoplasms
31
Urinary Bladder Neoplasms
30
Stomach Neoplasms
30
Lymphoma, Follicular
28
Interventions
pembrolizumab
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Has results
×
Spinocerebellar Degenerations
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts